Navigation Links
Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children
Date:3/5/2009

al corticosteroids are a mainstay in the treatment of atopic dermatitis. Now, newer formulations of topical corticosteroids in gels, foams and oils, which have undergone specific safety and efficacy testing, have been approved for use in younger patients -- including infants as young as three months of age. The products that are approved by the U.S. Food and Drug Administration (FDA) for this age group to treat atopic dermatitis and eczema include fluocinolone acetonide, topical oil 0.01%, desonide gel 0.05% and desonide foam 0.05%.

Dr. Eichenfield noted that some patients have expressed concern about the cost of treatments. Since major pharmacy retailers are promoting generic drug programs, patients may find a more cost-effective therapy for managing chronic atopic dermatitis.

"The newer approved formulations may cost more compared to the generic medications, so it is important for patients to discuss generic options with their dermatologist," said Dr. Eichenfield.

Topical Calcineurin Inhibitors

Another category of atopic dermatitis therapies used to suppress inflammation of the skin is topical calcineurin inhibitors, which includes the FDA-approved tacrolimus ointment and pimecrolimus cream. Recently, several new studies have examined whether the intermittent use of topical calcineurin inhibitors can effectively control atopic dermatitis. In patients whose atopic dermatitis was initially controlled with the application of topical corticosteroids or tacrolimus ointment, applying topical calcineurin inhibitors intermittently was effective in maintaining control of flare-ups.

"Studies have shown that topical calcineurin inhibitors can be very helpful in a variety of atopic dermatitis treatment regimens," said Dr. Eichenfield. "For instance, these recent studies demonstrate that applying topical tacrolimus ointment two to three times per week successfully controlled the cond
'/>"/>

SOURCE American Academy of Dermatology
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
2. Revolution Health and EmergingMed Launch Cancer Clinical Trial Matching and Referral Service
3. Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Marylands Emerging Company of the Year Award
4. Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder
5. LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
6. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
7. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
8. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
9. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
10. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
11. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 Research and Markets ( ... Regulatory Affairs in China (Basel, Switzerland - November 26-27, 2015)" ... will provide a detailed overview of the key areas of ... Hong Kong , Macau ... - All important aspects of gaining and maintaining ...
(Date:9/2/2015)... -- Seeger Weiss LLP is reporting that Zimmer Holdings Inc.,s ... 2015. Since the product was approved ... NexGen knee implant surpassed FDA investigation and mandatory product ... that the product is substantially similar to a preexisting ... In 2001, Zimmer began distributing High ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6x789c/new_eu ) has announced the ... UK - November 16-17, 2015)" conference to their ... concerning Pharmacovigilance are a major departure in terms of ... . The intention of the course is to ... they overlap and fit together and what Companies need ...
Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2
(Date:9/3/2015)... WI (PRWEB) , ... September 03, 2015 , ... At ... after becoming dissatisfied with the traditional health care model, where the primary care physician ... of individuals who want to become educated about their health issues and empowered to ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... announced that Bob Anders and Kelley Chapman will be joining the company’s executive ... , Anders has over 30 years’ experience in healthcare product and project ...
(Date:9/2/2015)... , ... September 03, 2015 , ... ... and frequently listed among the most influential leaders in healthcare, will offer the ... Coalition, to take place October 15-16, 2015, in Palm Harbor, Florida, at the ...
(Date:9/2/2015)... , ... September 02, 2015 , ... Chris Harrison of ... 2015. “It was a simple decision, really,” says Chris. “We have a lot of ... know the brands that work best for them—so we’ve given them the convenience of ...
(Date:9/2/2015)... , ... September 02, 2015 , ... Telehealth represents a ... Corp., contracted to handle the telehealth services of more than 12 Blues plan clients. ... Blue Shield Plans takes a look this growing trend, interviewing executives at Capital Blue ...
Breaking Medicine News(10 mins):Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 2Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 3Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:Harrison's Comfort Footwear Announces Expansion with New CHarrison Online Store 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3
... The experts reveal that lot more funds are needed from ... deaths of children under five by two-thirds.// ,Five ... experts, whose paper is one of the series of papers ... high-level meeting hosted by the journal, UNICEF and the Norwegian ...
... drug extensively used to treat acne can cause depression. ... animals.// ,Recently, the drug- Roaccutane, which effectively ... severe side-effects like suicidal behaviour. Though the packaging of ... occurrence of such side-effects is not known.,It has not ...
... an anti-cancer drug called Biomab-EGFR and had Shah Rukh Khan ... told reporters that the drug would be priced at 40 ... "Today we join the exclusive league of MAb developers worldwide. ... she added. She also told the drug was undergoing regulatory ...
... and Kashmir has a new problem to contend with now ... there are 745 such cases in the insurgency-hit state, unofficial ... there were only two cases reported, writes Grassroots Features. The ... the infection rate among the high-risk groups (STD-infected) at 0.95 ...
... arm in a motorcycle accident. She has become the first woman to ... own nerves. ,She talked about how she used it ... able to eat in a conventional way since her accident of over ... me.” ,Very often patients fitted with high-tech prosthetic limbs ...
... A new web site at the University of California, ... will enable people from around the world// to self-report ... other cholesterol drugs. ,“This line of research ... heart disease and cholesterol are familiar with the benefits ...
Cached Medicine News:Health News:Child death reduction needs five times more funds 2Health News:Acne drug may cause depression 2Health News:Kashmir Grapples with Growing AIDS 2Health News:Kashmir Grapples with Growing AIDS 3Health News:Bionic Women –No longer the Stuff of Science Fictio 2Health News:Patients Can Report Statins' Adverse Effects on New Web Site 2
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
Inquire...
... as either EDTA K2 or EDTA ... ions and therefore blocks the coagulation ... an EDTA anticoagulated blood sample are ... EDTA tubes are for the examination ...
Medicine Products: